Dr Patrick Forde speaks to ecancer about the phase 3 CheckMate 816 trial. It investigates nivolumab + platinum-doublet chemotherapy vs chemo as a neo-adjuvant treatment for resectable (IB-IIIA) NSCLC. Initially, he discusses the background of his study. He then explains the methodology and key results of this trial. The results from this phase III trial promotes the potential for anti-PD-1 immunotherapy to improve outcomes in earlier-stage NSCLC. Dr Forde says, ‘We are highly encouraged by the marked improvement in pCR, the overall good tolerability, and the absence of impact on surgery feasibility when nivolumab is added to neoadjuvant chemotherapy.’ The data from this trial accumulated to date from several retrospective studies show a clear trend that patients who achieve a pCR with neoadjuvant chemotherapy live longer than those who do not. In the end, Dr Forde discusses the future of this trial.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть